Efficacy: In a phase 2 clinical trial, orforglipron led to mean weight reductions of up to 12.6% over 36 weeks in people with obesity, a result comparable to injectable GLP-1 analogues [76]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.